Jump to:
Philip Wu joined the New York office of Ropes & Gray in 2022 and works in the corporate department. Philip represents public and private companies, investment banks, sponsors and investors in securities offerings, mergers and acquisitions, venture and minority equity financings and other strategic transactions. Philip also regularly advises clients on securities law reporting and compliance obligations, corporate governance and other general corporate matters.
Philip currently serves as a member of Northwestern University Pritzker School of Law’s Law School Fund Board.
Prior to law school, Philip worked and taught in the golf industry.
Experience
- Represented The Hanover Insurance Group in its $500 million senior notes offering.
- Represented Trinseo plc in connection with a transaction support agreement to, among other things, (i) redeem its existing $115 million 2025 Senior Notes with the proceeds of a new super holdco term loan, (ii) enter into a new $300 million super-priority revolving credit facility and (iii) exchange at least $330 million of 2029 Senior Notes for new 2029 Second Lien Senior Secured Notes at a discount to par, providing at least $49 million of discount capture.
- Represented Becton, Dickinson and Company in its $4.2 billion acquisition of the Critical Care business of Edwards Lifesciences Corporation.
- Represented Sanofi in connection with Toronto-based Zucara Therapeutics’ $20 million Series B financing.
- Represented Areteia Therapeutics, Inc. in its $75 million expansion of its Series A financing.
- Represented the underwriters in connection with HAT Holdings I LLC and HAT Holdings II LLC (each a subsidiary of HA Sustainable Infrastructure Capital, Inc.) offering $550 million aggregate principal proceeds of 8.00% Green Senior Unsecured Notes due 2027.
- Represented Paratek Pharmaceuticals, a biopharmaceutical company, in its $462 million take-private acquisition by Gurnet Point Capital and Novo Holdings.
- Represented Trinseo plc, a leading global specialty material solutions provider, and certain of its affiliates, in connection with a $1.1 billion innovative financing transaction addressing the Company’s near term maturities in September 2023.
- Represented Jounce Therapeutics, a clinical-stage immuno-oncology company, in its acquisition by Concentra Biosciences for $100 million plus contingent value rights.
- Ongoing representation of public company clients in connection with securities law and corporate governance matters.